The efficacy of additional metformin to aspirin for human rectal aberrant crypt foci: double-blinded randomized controlled trial

Phase 2

Recruiting

• Conditions: Colorectal adenoma, carcinoma in situ; Colorectal Neoplasm

• Registration Number: JPRN-jRCTs031180253
• Lead Sponsor: Misawa Noboru

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-13
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients both with rectal ACF and resectable polyps

Exclusion Criteria

1. Patients with lesion which preferred early resection.
2. History of regular use (defined as at least once per week) of NSAIDs and/or aspirin.
3. History of regular use of warfarin and/or DOAC.
4. History of diabetes mellitus (defined as more than HbA1c 6.5% or regular use of anti-diabetic drugs).
5.History of heart failure, renal failure, liver cirrhosis or chronic hepatic failure
6.History of familial adenomatous polyposis,
hereditary non-polyposis colorectal cancer and inflammatory bowel disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified